Celyad Oncology SA, a clinical-stage pharmaceutical company, is dedicated to discovering and developing CAR-T cell therapies that target cancer. Their foremost candidates include CYAD-101, an allogeneic CAR-T candidate that is currently in Phase 1b clinical trials for patients with metastatic colorectal cancer; CYAD-211, which focuses on short hairpin RNA (shRNA)-based allogeneic CAR-T therapy and is in Phase 1 clinical trials to treat relapsed or refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is currently in Phase 1 clinical trials for treating relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Celyad Oncology's licensing deals with Novartis International AG involve United States patents related to allogeneic CAR-T cells. Moreover, the company also works with Horizon Discovery Group plc to use shRNA reagents to reduce the expression of one or more defined targets. The company was previously known as Celyad SA but changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA, founded in 2004, maintains its main office in Mont-Saint-Guibert, Belgium.